ATE525393T1 - Immuntherapeutische formulierungen mit der fähigkeit, interleukin-2 zu neutralisieren - Google Patents

Immuntherapeutische formulierungen mit der fähigkeit, interleukin-2 zu neutralisieren

Info

Publication number
ATE525393T1
ATE525393T1 AT05811052T AT05811052T ATE525393T1 AT E525393 T1 ATE525393 T1 AT E525393T1 AT 05811052 T AT05811052 T AT 05811052T AT 05811052 T AT05811052 T AT 05811052T AT E525393 T1 ATE525393 T1 AT E525393T1
Authority
AT
Austria
Prior art keywords
ability
immunotherapeutic formulations
interleukin
neutralize
neutralize interleukin
Prior art date
Application number
AT05811052T
Other languages
English (en)
Inventor
Casimiro Jose Enrique Montero
Sarduy Livan Bladimir Alonso
Rodriguez Rolando Perez
Davila Agustin Bienvenido Lage
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Application granted granted Critical
Publication of ATE525393T1 publication Critical patent/ATE525393T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05811052T 2004-11-16 2005-11-16 Immuntherapeutische formulierungen mit der fähigkeit, interleukin-2 zu neutralisieren ATE525393T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20040261A CU23297A1 (es) 2004-11-16 2004-11-16 Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
PCT/CU2005/000009 WO2006053508A1 (es) 2004-11-16 2005-11-16 Formulaciones inmunoterapeuticas con capacidad neutralizante de la interleucina-2.

Publications (1)

Publication Number Publication Date
ATE525393T1 true ATE525393T1 (de) 2011-10-15

Family

ID=40122436

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05811052T ATE525393T1 (de) 2004-11-16 2005-11-16 Immuntherapeutische formulierungen mit der fähigkeit, interleukin-2 zu neutralisieren

Country Status (25)

Country Link
US (1) US20090274647A1 (de)
EP (2) EP2112160B1 (de)
JP (1) JP5227028B2 (de)
KR (1) KR101240457B1 (de)
CN (1) CN101061136B (de)
AR (1) AR051494A1 (de)
AT (1) ATE525393T1 (de)
AU (1) AU2005306186B2 (de)
BR (1) BRPI0518007A (de)
CA (1) CA2588573C (de)
CR (1) CR9097A (de)
CU (1) CU23297A1 (de)
EA (1) EA012072B1 (de)
GE (1) GEP20105039B (de)
HK (1) HK1113374A1 (de)
MA (1) MA29044B1 (de)
MX (1) MX2007005808A (de)
MY (1) MY162106A (de)
PE (1) PE20061172A1 (de)
SG (1) SG122897A1 (de)
TN (1) TNSN07187A1 (de)
TR (1) TR200704213T2 (de)
TW (1) TWI433853B (de)
WO (1) WO2006053508A1 (de)
ZA (1) ZA200703528B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
WO2015162124A1 (en) * 2014-04-22 2015-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnostic of an autoimmune disease
JP7030689B2 (ja) * 2015-10-23 2022-03-07 ファイザー インコーポレイティッド 抗ｉｌ－２抗体ならびにその組成物及び使用
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CU20210021A7 (es) * 2021-03-30 2022-11-07 Ct Inmunologia Molecular Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939832A (ja) * 1982-08-28 1984-03-05 Ajinomoto Co Inc モノクロ−ナル抗体ならびにその製法、使用法
EP0111344A2 (de) * 1982-12-13 1984-06-20 Sloan-Kettering Institute For Cancer Research Monoklonale Anti-Interleukin-2-Antikörper
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
CA2063271A1 (en) * 1989-07-14 1991-01-15 Subramonia Pillai Cytokine and hormone carriers for conjugate vaccines
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US20040156824A1 (en) * 1996-12-23 2004-08-12 Epstein Alan L. Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CA2219961C (en) * 1998-01-09 2010-06-01 The University Of Southern California Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
RU2236251C2 (ru) * 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
US20020022030A1 (en) * 2000-04-26 2002-02-21 Philippa Marrack Product and process for regulation of T cell responses
CU23011A1 (es) * 2000-11-03 2004-12-17 Ct Ingenieria Genetica Biotech Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
WO2002087304A2 (de) * 2001-04-30 2002-11-07 Frohnhofen, Wilfried Il2-peptide; von interleukin 2 abgeleitete peptide und peptid-dimere
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
ITMI20012527A1 (it) * 2001-11-30 2003-05-30 Unihart Corp Proteine di fusione contenenti peptidi tlp
US7247615B2 (en) * 2001-11-30 2007-07-24 United States Of America, Represented By The Secretary, Department Of Health And Human Services Peptide agonists of prostate-specific antigen and uses therefor
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
WO2005007121A2 (en) * 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides

Also Published As

Publication number Publication date
MY162106A (en) 2017-05-31
EA012072B1 (ru) 2009-08-28
EP1829893B1 (de) 2011-09-21
GEP20105039B (en) 2010-07-12
PE20061172A1 (es) 2006-12-16
WO2006053508A1 (es) 2006-05-26
EA200701071A1 (ru) 2007-12-28
JP2008526686A (ja) 2008-07-24
MX2007005808A (es) 2007-07-20
JP5227028B2 (ja) 2013-07-03
CA2588573C (en) 2013-12-31
AR051494A1 (es) 2007-01-17
HK1113374A1 (en) 2008-10-03
TR200704213T2 (tr) 2007-08-21
CA2588573A1 (en) 2006-05-26
EP2112160A2 (de) 2009-10-28
EP2112160A3 (de) 2010-01-13
BRPI0518007A (pt) 2008-10-21
CN101061136B (zh) 2012-12-05
EP2112160B1 (de) 2015-07-08
AU2005306186B2 (en) 2012-05-31
AU2005306186A1 (en) 2006-05-26
EP1829893A1 (de) 2007-09-05
CR9097A (es) 2007-08-28
KR20070084025A (ko) 2007-08-24
US20090274647A1 (en) 2009-11-05
CU23297A1 (es) 2008-07-24
ZA200703528B (en) 2008-06-25
KR101240457B1 (ko) 2013-03-08
TNSN07187A1 (en) 2008-11-21
TW200631591A (en) 2006-09-16
CN101061136A (zh) 2007-10-24
TWI433853B (zh) 2014-04-11
MA29044B1 (fr) 2007-11-01
SG122897A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
DE602005022897D1 (de) Piperidinylamino-thienoä2,3-dü-pyrimidinverbindungen
NO20053161D0 (no) Mikrobedrepende sammensetning.
NL1028967A1 (nl) 4-Fenylamino-chinazoline-6-yl-amiden.
IS2744B (is) Tæki til þess að öngla, ásamt möguleika til þess að beita línu
NO20051522D0 (no) Kabelskjotbeskytter.
NO20053210D0 (no) Linneslakkompensator.
DK2468732T3 (da) 1H-Quinazolin-2,4-dioner
FI20050106A (fi) Matkaviestinlaite
NO20052746D0 (no) Avlopsenhet.
NO20041374D0 (no) Bolgekraftverk.
ATE525393T1 (de) Immuntherapeutische formulierungen mit der fähigkeit, interleukin-2 zu neutralisieren
NO20052482D0 (no) Redningskokong.
DE602006004566D1 (de) Substituierte pyrrole, zusammensetzungen, die dieshre verwendung
DE602005012921D1 (de) Flachbildschirm
DE602004012067D1 (de) Antenneneinheit
NO20040762L (no) Stromskinne.
FR2876232B3 (fr) Convertisseur-thermo-electrique solaire
FI20040780A0 (fi) Matkaviestin
NL1025196A1 (nl) Hark-Zeef-Vork.
ITRM20040037A1 (it) La digitopressione per strapiantare.
ITTV20040063A1 (it) Struttura di aratro.
FI20041628A0 (fi) Kolmiulotteinen, optinen mittausjärjestelmä
ES1058702Y (es) Escalera de mano.
SE0402601D0 (sv) Novel use
SE0400092D0 (sv) Novel use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties